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Recent studies showed that the nisin modification machinery can successfully dehydrate serines and threoni-
nes and introduce lanthionine rings in small peptides that are fused to the nisin leader sequence. This opens
up exciting possibilities to produce and engineer larger antimicrobial peptides in vivo. Here we demonstrate the
exploitation of the class I nisin production machinery to generate, modify, and secrete biologically active,
previously not-yet-isolated and -characterized class II two-component lantibiotics that have no sequence
homology to nisin. The nisin synthesis machinery, composed of the modification enzymes NisB and NisC and
the transporter NisT, was used to modify and secrete a putative two-component lantibiotic of Streptococcus
pneumoniae. This was achieved by genetically fusing the propeptide-encoding sequences of the spr1765 (pneA1)
and spr1766 (pneA2) genes to the nisin leader-encoding sequence. The chimeric prepeptides were secreted out
of Lactococcus lactis, purified by cation exchange fast protein liquid chromatography, and further character-
ized. Mass spectrometry analyses demonstrated the presence and partial localization of multiple dehydrated
serines and/or threonines and (methyl)lanthionines in both peptides. Moreover, after cleavage of the leader
peptide from the prepeptides, both modified propeptides displayed antimicrobial activity against Micrococcus
flavus. These results demonstrate that the nisin synthetase machinery can be successfully used to modify and
produce otherwise difficult to obtain antimicrobially active lantibiotics.
Small antimicrobial peptides produced by Gram-positive
bacteria are named bacteriocins. One group of bacteriocins,
the nonlantibiotics, comprises peptides that do not require
modification for their antimicrobial activity (46). Members of
another group, the lantibiotics, require posttranslational mod-
ifications to acquire biological activity (11, 47). Lantibiotics are
produced as inactive prepeptides, consisting of an N-terminal
leader peptide and a C-terminal propeptide part. Most of the
serine and threonine residues of the propeptide are dehy-
drated to dehydroalanine (Dha) and dehydrobutyrine (Dhb),
respectively, by LanB- or LanM-type enzymes (“Lan” is a gen-
eral abbreviation for proteins involved in lantibiotic biosynthe-
sis). LanC or LanM enzymes can subsequently couple these
dehydroresidues to cysteines, thus forming a (methyl)lanthi-
onine ring. After the leader peptide is removed from the
prepeptide by the extracellular LanP or transmembrane LanT
proteins, the active lantibiotic is released. The immunity
against the produced lantibiotics is provided by the LanI
and/or LanFEG proteins (3, 21, 41). Three classes of lantibi-
otics are distinguished (47). Class I lantibiotics are modified by
two enzymes, LanB and LanC. In class II lantibiotics, dehy-
dration and cyclization are performed by a single enzyme
called LanM. The C-terminal sequences of LanM-type en-
zymes share homology with the LanC proteins. LanM enzymes
share no homology with the LanB proteins (36, 45). Class II
also includes two-component lantibiotics, of which antimicro-
bial activity depends mainly on the synergistic action of both
peptides (33, 34). Each of the peptides of the two-component
lantibiotics, except cytolysin, possesses its own dedicated mod-
ification LanM enzyme. Class III consists of lantibiotics with
functions other than antimicrobial activity (17, 48).
Due to an increasing resistance of bacteria to available an-
tibiotics, there is an urgent need to search for substances active
against multidrug resistant pathogens. Since some lantibiotics
exhibit a stable activity at nanomolar concentrations against
antibiotic-resistant pathogens, it is currently of great interest to
apply lantibiotics (6, 32, 40). It has already been shown with a
mouse model that mersacidin is active against methicillin-
resistant Staphylococcus aureus (MRSA) strains (18). An-
other lantibiotic, lacticin 3147, is a successful antimicrobial
agent against MRSA, vancomycin-resistant Enterococcus
faecalis, penicillin-resistant Streptococcus pneumoniae, Pro-
pionibacterium acnes, and Streptococcus mutans (8).
One of the most studied lantibiotics is nisin (9, 10, 22, 27), a
class I lantibiotic produced by certain Lactococcus lactis
strains. It has a long record of safe industrial use as a food
preservative (6). Due to the broad activity spectrum against
Gram-positive pathogens, including S. pneumoniae, nisin has
good potential for a number of other applications (9). Re-
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cently, it was shown that designed hexapeptides and nonlan-
tibiotic peptides fused to the leader peptide of nisin could be
successfully modified by NisB and NisC and exported out of
L. lactis via NisT (16, 20, 38). The discovery that the lantibiotic
modification enzymes LanB, LanC, and LanM possess rather
low substrate specificities brings a new opportunity to use them
as a tool to improve the stability and activity of peptides po-
tentially valuable for medical applications (2, 16, 39).
Here, we present the successful application of the nisin ex-
pression/modification system to produce, modify, and secrete
entirely unrelated putative lantibiotics that, based on bioinfor-
matic predictions, belong to the class II lantibiotics. The pro-
duced peptides were dehydrated multiple times, as shown by
matrix-assisted laser desorption ionization–time of flight
(MALDI-TOF) mass spectrometry. Importantly, the modified
peptides showed antimicrobial activity against Micrococcus fla-
vus. Our study demonstrates that the nisin production/modifi-
cation machinery can be used to produce and posttranslation-
ally modify silent lantibiotics, i.e., those for which production
conditions are not known, that otherwise would be difficult to
obtain from their natural sources.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Strains and plasmids used in this
study are listed in Table 1. Strains were stored in 10% (vol/vol) glycerol at
280°C. Streptococcus pneumoniae, Enterococcus faecalis, Staphylococcus aureus,
and Streptococcus mitis strains were grown at 37°C in standing M17 (Difco) broth
supplemented with 0.5% (wt/vol) glucose (GM17) and, when appropriate, 2
mg/ml chloramphenicol. Lactococcus lactis and Micrococcus flavus were grown at
30°C in GM17 or minimal medium (39) supplemented with 5 mg/ml chloram-
phenicol and/or 5 mg/ml erythromycin when appropriate.
Construction of chimeric peptides. Standard genetic manipulations were per-
formed essentially as described by Sambrook et al. (43). Plasmid pIL3BTC
encoding the nisin modification machinery (39) and plasmid pNZnisA-E3 (19)
were used to produce and modify chimeric peptides. Briefly, two open reading
frames, spr1765 and spr1766 (pneA1 and pneA2, respectively), were amplified by
PCR from genomic DNA of S. pneumoniae R6 and cloned into pNG8048E,
resulting in a plasmid, named pNGspr1765-1766, for which L. lactis NZ9000 (39)
was used as a host. All the subsequent genetic cloning procedures were per-
formed with this organism. This plasmid, pNGspr1765-1766, served as a template
to amplify separately the genes spr1765 and spr1766. Subsequently, each of
the amplified products of genes spr1765 and spr1766 was subcloned to the
pNZnisA-E3 expression plasmid. This resulted into two new plasmids, pNZE3-
nis-spr1765 and pNZE3-nis-spr1766, which carried the nisin structural gene and
a lantibiotic gene next to one another. To construct genetic fusions of the nisin
leader sequence and the structural leaderless sequence of the spr1765 and
spr1766 (pneA1 and pneA2, respectively) genes in frame, the round PCR method
with 59-phosphorylated primers was used as described previously (39), using
Phusion DNA polymerase (Finnzymes). The final chimeric peptide expression
plasmids pNZE3-spr1765 and pNZE3-spr1766 were thus constructed. These
plasmids were used separately in combination with plasmid pIL3BTC to produce
and secrete modified chimeric peptides. Plasmid isolation was performed by
means of the plasmid DNA isolation kit (Roche Applied Science). Restriction
analysis was performed with restriction enzymes from Fermentas. DNA ligation
was performed with T4 DNA ligase (Fermentas).
Peptides. Peptides encoding the sequence of leaderless PneA1 and PneA2
were purchased from Pepscan Lelystad NL. Peptides were purified to homoge-
neity by high-pressure liquid chromatography (HPLC) on a Jupiter Proteo C12
(4-mm, 90-Å, 250- by 4.6-mm) column with an acetonitrile gradient.
Expression and purification of microbially produced peptides were performed
as follows. Overnight cultures of L. lactis NZ9000 containing pIL3BTC and a
chimeric peptide expression plasmid, namely, pNZnisA-E3, pNZE3-spr1765, or
pNZE3-spr1766, in GM17 were diluted 1:50 in minimal medium containing
appropriate antibiotics and 0.5 ng/ml nisin (Sigma) for induction. Cultures were
grown for 24 h at 30°C. Subsequently, supernatants were separated from cells by
centrifugation. Next, supernatants were filtered through a 0.2-mm filter (Milli-
pore). Prior to purification on a 5-ml HiTrap SP cation exchange column (GE
Healthcare) using fast protein liquid chromatography (FPLC; on an A¨kta puri-
fier; Amersham Biosciences), supernatants were diluted 1:1 with a 100 mM lactic
acid solution and filtered through 0.2-mm filters. After passage of supernatant
through a column, unbound compounds were washed away with 100 mM lactic
acid. Elution was performed with 1 M NaCl in 50 mM lactic acid solution. The
fractions containing prepeptides were concentrated and desalted with 50 mM
Tris-HCl of pH 5.5 on Microcon columns (Milipore). Intact prepeptides and
peptides without a leader sequence were analyzed with MALDI-TOF mass
spectrometry and used for screening of antimicrobial activity.
N-terminal sequence removal. The N-terminal sequence from the FPLC-
purified prepeptides prePneA1 and prePneA2 was removed by trypsin. Prepep-
tides were incubated for 2 h at 37°C with 20 mg/ml trypsin in 100 mM Tris-HCl
buffer (pH 8) containing 10 mM CaCl2. Alternatively, to remove the leader from
prePneA2, 180 ml of the prepeptide was incubated for 30 min at 37°C with 20 ml
TABLE 1. Strains and plasmids used in this study
Strain/plasmid Descriptionb Reference or source
Strains
S. pneumoniae R6 D39 (Dcps2 2538–9862) with increased transformation efficiency 14
L. lactis NZ9000 MG1363 DpepN::nisRK 15
S. aureus RN6390B Lab collection
S. mitis NTCC10712 Lab collection
E. faecalis V583 42
M. flavus NIZO B423 NIZO food researcha
Plasmids
pIL3BTC nisBTC, encoding nisin modification machinery; Eryr 39
pNZ8048 Nisin-inducible PnisA; Cmr 7
pNG8048E Nisin-inducible PnisA, pNZ8048 derivative containing Eryr gene to
facilitate cloning; Cmr Eryr
Lab collection
pNZnisA-E3 nisA, encoding nisin 19
pNZE3-nis-spr1765 Contains nisA gene and SPR1765 gene This work
pNZE3-nis-spr1766 Contains nisA gene and SPR1766 gene This work
pNZE3-spr1765 Contains a part of nisA gene which encodes leader peptide of nisin
and leaderless part of SPR1765 gene fused in frame
This work
pNZE3-spr1766 Contains a part of nisA gene which encodes leader peptide of nisin
and leaderless part of SPR1766 gene fused in frame
This work
pNGspr1765-1766 pNG8048E contains spr1765 and spr1766 genes under own promoter This work
a Dutch Institute of Dairy Research.
b Eryr, erythromycin resistance; Cmr, chloramphenicol resistance.


















































of 0.5 M phosphate buffer (pH 7.4) and with 10 ml of leucine aminopeptidase
(Sigma; suspension in 3.5 M ammonium sulfate).
Mass spectrometry analysis. To investigate whether chimeric peptides possess
free cysteine residues, reactions with 1-cyano-4-dimethylaminopyridinium tet-
rafluoroborate (CDAP) were performed. To obtain higher mass spectrum reso-
lutions with MALDI-TOF, both prepeptides and propeptides, prior to CDAP
treatment, were purified on a Hewlett Packard 1050 HPLC apparatus using a
Jupiter Proteo C12 (4-mm, 90-Å, 250- by 4.6-mm) column. Reverse-phase puri-
fication was used with a gradient of 10% to 40% acetonitrile in purified water. All
buffers contained 0.1% trifluoroacetic acid (TFA). The reactions with CDAP
were performed as described previously (16, 35). Briefly, the pH of vacuum-dried
trypsinated and nontrypsinated peptides and a control peptide, termed NisB2
(H-CRYTDPKPHIRLRIK-OH), resuspended in 16 ml MilliQ was adjusted to 2
or 3 with 0.1% TFA. Prior to treatment with CDAP, 1 ml of a 100-mg/ml
concentration of the reducing agent triscarboxyethyl phosphine (TCEP) was
added to each mixture, and a reaction was carried out for 5 min at room
temperature. Subsequently, 2 ml of 100 mg/ml CDAP was added to the mixtures,
and incubation followed for 15 min at room temperature.
Analysis was performed essentially as described before (19). Briefly, ZipTips
(C18 ZipTip; Millipore) were wetted with 100% acetonitrile and washed with
0.1% TFA. Subsequently, the supernatant containing the peptides was mixed
with 0.1% TFA and applied to a ZipTip. Peptides that were bound to the column
were washed with 0.2% TFA and eluted with 50% acetonitrile and 0.1% TFA.
The eluent was mixed in a ratio of 1:1 with 10 mg/ml a-cyano-4-hydroxycinnamic
acid (matrix). A total of 1.5 ml of this prepared mixture was spotted on the target
and allowed to dry. Mass spectra were recorded with a Voyager-DE Pro (Applied
Biosystems) MALDI-TOF. In order to increase the sensitivity, external calibra-
tion was applied with six different peptides (protein MALDI-MS calibration kit;
Sigma).
Amino acid sequence alignment. Amino acid sequence alignment of nisin with
pneumococcins A1 and A2 (SPR1765 and SPR1766, respectively) was performed
with Clustal W (25), a program for multiple sequence alignments. The peptide
sequences were derived from the NCBI database.
Gel electrophoresis. Prepeptides and mature peptides were analyzed on Tris-
Tricine gels (44) and stained with Coomassie (Fermentas).
Peptide concentration determination. Peptide concentrations were deter-
mined using the DC protein assay of Bio-Rad. HPLC-purified nisin was used as
a standard.
MIC determination. MIC assays for M. flavus, S. pneumoniae, E. faecalis, S.
aureus, and S. mitis were performed in 96-well microtiter plates in GM17. The
assay was performed as follows. Overnight cultures of the above-mentioned
strains were diluted 1:50, and growth was continued to an optical density at 600
nm (OD600) of 0.2. Subsequently, 150-ml cultures were mixed with 50 ml of
appropriate medium and various concentrations of peptides. The microtiter
plates were incubated in a GENios (TECAN Benelux) at a suitable temperature
for overnight growth of the strain, and the OD600 was measured every 30 min.
The MIC values were determined at the time when the cells without antimicro-
bial substance reached half of the maximal optical density. MICs were calculated
from the lowest concentration of the antimicrobial substance that was able to
inhibit the growth of the tested strain. All the susceptibility assays were per-
formed in triplicate at least.
RESULTS
In silico analysis of the putative two-peptide lantibiotic-like
cluster from S. pneumoniae. After in silico analysis of 11 puta-
tive bacteriocin genes, identified by BAGEL (5), of S. pneu-
moniae R6 and their adjacent open reading frames (ORFs), we
selected two of them, i.e., spr1765 and spr1766. In silico analysis
of these two genes, as well as their nine adjacent ORFs, which
most likely constitute a single cluster (Fig. 1), indicated that
SPR1765 and SPR1766 belong to the class II two-component
lantibiotics. We here propose to name SPR1765 and SPR1766
pneumococcins A1 and A2 (PneA1 and PneA2), respectively. So
far there are no experimental data indicating that these bacteri-
ocin-like peptides are expressed under laboratory growth condi-
tions or in or under any other growth media or conditions we have
tried (data not shown). In silico analysis showed that the nine
adjacent genes (Fig. 1) are likely involved in pneumococcin A1
and A2 modification, transport, processing, and immunity.
Gene spr1767 encodes a protein with amino acid sequence
similarity to a classic bifunctional LanM-like modification
enzyme. The spr1768 gene encodes a putative flavin adenine
dinucleotide (FAD)-dependent flavoprotein that could cat-
alyze the oxidative decarboxylation of C-terminal residues.
The functions of SPR1764, SPR1769, and SPR1774 are un-
known. The SPR1770 protein is a predicted ABC trans-
porter containing putative N-terminal double-glycine pepti-
dase activity (peptidase of C39 family) and is most likely
responsible for transport of modified bacteriocins and for
prepeptide processing. The SPR1771 protein shares 48%
identity with NisP, the nisin leader peptidase. The last two
genes of the regulon, spr1772 and spr1773, encode a putative
immunity protein and a putative ABC transporter, respec-
tively. This analysis clearly shows that PneA1 and PneA2
very likely belong to the class II two-component lantibiotics.
Additionally, the gene cluster encoding the pneumococcins
contains the gene encoding a putative flavoprotein (the spr1768
gene product). The gene encoding this type of enzyme is also
found in the gene clusters of epidermin and mersacidin. The
modifications made by the flavoproteins are required for full
activity of these peptides (24, 29). Whereas NisT displays rather
broad transport specificity of peptides fused to the leader peptide
of nisin, NisP has been shown to process only fully modified
prenisin (19). Figure 2 shows the amino acid sequence alignment
of pneumococcins A1 and A2 with the nisin structural peptide.
There is a low similarity between the peptides both in the part of
the leader sequence and in the part of the propeptide. On the
basis of lantibiotic leader sequences (Fig. 2), the predicted pneu-
mococcin A1 and A2 peptides possess three candidate cleavage
sites, one behind GlyGly/GlyAla (after which SPR1770 might
cleave), one behind a shared GlyAla sequence, and one behind
ProArg. Strikingly, prenisin, prePneA1, and prePneA2
share the sequence GAxPRxT (the x being a variable resi-
due), which comprises in the middle the site behind ProArg.
These data, together with the shared 48% identity of the
putative leader peptidase, SPR1771, with NisP, indicate that
the Pne leader peptides end with ProArg.
FIG. 1. Putative pneumococcin A1 and A2 gene cluster. Organization of the chromosomally located biosynthetic gene cluster of pneumococcin
A1 and A2 genes (spr1765 and spr1766, respectively) in S. pneumoniae. ORFs are represented by thick gray arrows, and their SPR gene
identification numbers are shown in the gray arrows. The putative promoters are represented by thin and bent black arrows.


















































Production, secretion, and purification of the chimeric pep-
tides. To investigate the production and secretion of chimeric
peptides, pNZE3-spr1765 and pNZE3-spr1766 were introduced
into L. lactis NZ9000 containing pIL3BTC. Cultures of L. lactis
NZ9000 plasmid-containing derivatives induced with nisin were
grown for 24 h in minimal medium. Subsequently, the superna-
tants were collected, and the prepeptides were purified on a
HiTrap SP cation exchange column. The same procedure was
applied for prenisin, a positive control. All prepeptides were pro-
duced and secreted, as visualized by Tris-Tricine electrophoresis
(Fig. 3). Prepeptide concentrations were determined with HPLC-
purified nisin of known concentration, as a reference. Without
nisin induction, no secreted peptides were observed (data not
shown). The production levels of both prePneA1 and prePneA2
were approximately 50% lower than that of prenisin.
Streptococcal chimeric peptides are modified by nisin syn-
thetase enzymes. To test whether the purified chimeras
prePneA1 and prePneA2 were modified, they were analyzed
by MALDI-TOF spectrometry. Table 2 presents a summary of
the obtained masses. Interestingly, analysis of prePneA1 and
prePneA2 showed that both prepeptides were modified multi-
fold. PrePneA1 showed four- and threefold dehydrations and
prePneA2 four-, three-, and twofold. Chimeric prepeptides
were processed by trypsin or leucine aminopeptidase and fur-
ther characterized. Since the leader peptide keeps the prepep-
tide inactive, its removal allows the assessment of the antimi-
crobial activity of the mature peptides. Trypsin cleaves a
peptide bond behind lysine or arginine, with arginine being
preferred over lysine, allowing arginine-specific cleavage under
controlled conditions (Table 2).
The prePneA1 was processed by trypsin, and only the nisin
leader sequence was clipped off, leaving the mature peptide
with multiple dehydrations (Table 2). However, prolonged di-
gestion at a higher concentration of trypsin resulted in two
additional mass peaks corresponding to two fragments (Table
2). The N-terminal part of PneA1 (Table 2) was cleaved off and
showed no dehydrations, likely due to protection against de-
hydration of Ser/Thr by their directly flanking residues (39).
The identity of this N-terminal fragment was confirmed by
sequence data obtained by postsource decay (data not shown).
The other lysine residue in the mature peptide (SSK) appears
protected against proteolysis, likely due to posttranslational
modifications in its vicinity (26). The five dehydrations that
were observed with the mature PneA1 are therefore located in
the C-terminal part of the peptide, in which six serines are
present. Since one of those serines is located next to the lysine
that is cleaved by trypsin, it is most likely that the observed
dehydrations are all within the last 25 amino acids of PneA1,
except for the first serine at SSK.
PneA2 contains a number of residues that are substrates for
trypsin, and some of them are not protected by modified res-
idues (Fig. 2). Therefore, we initially obtained a smaller frag-
ment (Table 2, PneA2 fragment 2), which lacked the C-termi-
nal extension but contained multiple dehydrated residues.
Additionally, in HPLC-purified chimeric prePneA2, there was
also a clear fraction containing a peptide fragment consisting
of part of the nisin leader sequence and the N-terminal part of
the PneA2 peptide (Table 2, prePneA2 fragment 1). Interest-
ingly, this peptide fragment contained up to four dehydrations,
which clearly shows that four out of five dehydrated residues
are located in the first 11 amino acids of the mature peptide.
Subsequently, removal of the N-terminal leader peptide
from chimeric peptides by NisP overexpressed in L. lactis was
also investigated. However, neither the release of the leader
peptide nor the antimicrobial activity of PneA1 or PneA2 was
detected (data not shown). Intact PneA2 was obtained using
leucine aminopeptidase and appeared to be three- to sixfold
dehydrated (Table 2). Importantly, the activity of the leucine
aminopeptidase apparently had stopped after the last Arg.
This indicates the presence of a thioether bridge starting at
either Ser1 or Thr2. Studies by Rink et al. indicated that
flanking hydrophilic residues on both sides of a Ser or Thr
would not favor dehydration. Furthermore, serines are less
readily dehydrated than threonines (39). Therefore, a large
extent of the dehydration of Ser1 flanked by Arg and Thr is not
likely. Taken together, these findings indicate that Thr2 is fully
dehydrated and is thioether cross-linked to Cys5.
To investigate whether thioether rings were formed, CDAP,
which reacts only with free cysteines, was used. The control
NisB2 peptide that contains one free cysteine was used as a
positive control (not shown) for CDAP modification. CDAP
modification converts a free thiol group of cysteine into an
isothiocyanate, yielding a mass increase of 25 Da. The fivefold
dehydrated PneA1 showed hardly any CDAP modification,
FIG. 2. Amino acid sequence alignment of nisin with pneumococcins A1 and A2. The cleavage site in the peptide sequence is highlighted in
gray. Identical amino acid residues for all three sequences are indicated by an asterisk, conserved residues by a colon, and semiconserved amino
acids by a point.
FIG. 3. Tris-Tricine gel illustrating trypsin-treated and non-trypsin-
treated purified chimeric peptides and nisin. Lane M, marker; lane 1,
prePneA1; lane 1A, trypsin-treated PneA1; lane 2, prePneA2; lane 2A,
trypsin-treated PneA2; lane 3, prenisin; lane 3A, trypin-treated prenisin.


















































indicating that there were no free cysteine residues and thus
the formation of two thioether rings. The threefold dehydrated
PneA1 peptide showed single and double CDAP modifica-
tions, indicating the formation of either one or no thioether
rings (Fig. 4). Similar studies of CDAP modification of
PrePneA2 indicated the presence of two thioether rings in the
extensively dehydrated peptides (not shown). These data dem-
onstrate that the putative lantibiotics, which are entirely unre-
lated to nisin, can be successfully produced, modified, and
secreted by the nisin synthetase machinery.
The produced and modified peptides have significant anti-
microbial activity. To investigate the antimicrobial activity of
the modified peptides, the chimeric prepeptides were incu-
bated with trypsin or leucine aminopeptidase to remove the
N-terminal leader sequence. Various dilutions of trypsin-
treated peptides, namely, prenisin (positive control) and pneu-
mococcins A1 and A2, were tested for antimicrobial activity in
the MIC assay (Table 3). Of all microorganisms tested, i.e., M.
flavus, S. pneumoniae, E. faecalis, S. aureus, and S. mitis, only
M. flavus was susceptible to the tested peptides, i.e., PneA1 and
PneA2 (Table 3). In control experiments, no significant inhi-
bition was found with either buffer or bovine serum albumin
(BSA) treated with trypsin or with empty samples, i.e., frac-
tions from prepeptide purifications that did not contain pep-
tides (Table 3). Additionally, undigested chimeric prepeptides
did not show significant antimicrobial activity against the indi-
cator strain (Table 3). Unmodified PneA1 (MIC of .50 mM)
and PneA2 (MIC of .1.5 mM) propeptides obtained by chem-
ical synthesis were at least 30-fold and 170-fold less active,





Mass (M 1 H1) without
Met1 (Da)
Observed Calculated
prePneA1 (nisin leader WTPTPIILKSAAASSKVCISAAVSGIGGLVSYNNDCLG) 4 6,009.6 6,009.9
3 6,026.5 6,027.9




PneA1 (fragment 1 WTPTPIILK) 0 1,068.9 1,069.3
PneA1 (fragment 2 SAAASSKVCISAAVSGIGGLVSYNNDCLG) 4 2,643.6 2,644.0
3 2,662.0 2,662.0
2 2,680.5 2,680.0
prePneA2 (nisin leader STIICSATLSFIASYLGSAQTRCGKDNKKK) 4 5,437.6 5,437.2
3 5,454.0 5,455.3
2 5,472.2 5,473.3




prePneA2 (fragment 1 SKKDSGASPRSTIICSATLSF) 4 2,085.1 2,084.7
3 2,103.1 2,102.7






a The average masses are shown.
FIG. 4. Modified PneA1 contains thioether bridges. The SAAASS
KVCISAAVSGIGGLVSYNNDCLG fragment dehydrated fourfold,
threefold, and twofold (solid line) is treated with CDAP (dotted line)
to detect the presence of modifiable cysteines (yielding peptide plus 25
Da) and nonmodifiable thioether linkage-forming cysteines. The
2,643.6-Da peak which is dehydrated fourfold shows a mild single
CDAP addition. The 2,661.9-Da (threefold-dehydrated) peak shows sin-
gle and double CDAP additions, as indicated by black arrows. The
2,680.5-Da (twofold-dehydrated) peak shows clear single and double
CDAP additions; 1 CDAP, 2,705.3 Da (plus 25 Da), and 2 CDAP, 2,729.8
Da (plus 50 Da). The fivefold-dehydration peak is becoming visible after
CDAP addition, indicating that this peptide has two thioether rings.


















































respectively, than the HPLC-purified active fraction of the
corresponding NisBC-modified peptides, without leader pep-
tide. This proves that NisBC-induced modifications are re-
quired for lantibiotic activity. PneA1 inhibited the growth of M.
flavus at a peptide concentration of 0.6 mM. PneA2, from
which the leader sequence was removed by either trypsin or
leucine aminopeptidease, inhibited growth at approximately 10
or 8.5 mM, respectively (Table 3). The combination of both
modified chimeric peptides, PneA1 and PneA2, did not act
synergistically (Table 3). Thus, the data demonstrate that it is
possible to utilize the nisin synthetase machinery for the pro-
duction of antimicrobially active peptides unrelated to nisin.
DISCUSSION
To the best of our knowledge, we present here for the first
time the successful expression, modification, secretion, and
biological activity of novel class II lantibiotics by the nisin
synthetases, which normally produce nisin, a class I lantibiotic.
To present a significant challenge as substrate peptides, pneu-
mococcins A1 and A2 from S. pneumoniae R6, which presum-
ably belong to the class II two-component lantibiotics, were
chosen as substrates for the nisin enzymes. The class II two-
component lantibiotics require a LanM-type enzyme that per-
forms both dehydration and cyclization, whereas class I lan-
tibiotics require LanB dehydratases and LanC cyclases. It has
already been shown that LanBC-type enzymes can modify pep-
tides other than nisin which are fused to the nisin leader
sequence. Kluskens et al. and Kuipers et al. demonstrated that
both medically relevant nonlantibiotic peptides and a trun-
cated lantibiotic, lacticin 3147, that were fused with the nisin
leader sequence, modified by NisB and NisC, were exported
via NisT and contained dehydrated amino acids and lanthio-
nine rings (16, 20). The same was proven by Rink et al. for
various hexapeptides (38, 39). Thus, based on the discovery
that the nisin synthetase machinery can accept various peptides
as templates for modification, the propeptide part, which is the
predicted maturating part of either the PneA1 or the PneA2
peptide, was fused to the nisin leader sequence and introduced
into L. lactis that overexpresses NisBTC. The produced pep-
tides were dehydrated multifold and contained thioether rings.
Some dehydrated residues and one thioether ring could be
localized by studying peptide fragments and by applying
leucine aminopeptidase.
To be biologically active, lantibiotics require prepeptide pro-
cessing, i.e., removal of the leader sequence. The prepeptide
sequences and the homology of the peptidase with NisP indi-
cate that the site behind PR might be the processing site from
which the propeptide starts. To liberate the mature peptides,
we used trypsin or leucine aminopeptidase. Exported, purified,
and processed peptides were tested for antimicrobial activity,
and M. flavus was found to be highly susceptible to both the
PneA1 and PneA2 peptides. Despite the fact that PneA1 and
PneA2 are predicted two-component lantibiotics, we did not
observe any significant synergistic effect when these peptides
were combined (data not shown). The PneA1 and PneA2 pep-
tides are a mixture of extensively modified and hardly modified
peptides. These mixtures probably contain active, less active,
and inactive peptides. Thus, the determined antimicrobial ac-
tivity is the mean of the activities of all these peptides, indi-
cating that the specific activity for a single active peptide might
be higher. With respect to this, a preliminary experiment was
performed with processed and NisBC-modified PneA1 and
PneA2 peptides which were dehydrated four- and fivefold,
separated, and purified from the total mixture. However, the
MICs of both peptides were not significantly different from the
MICs of the unpurified peptides (data not shown). A challenge
for future work might be to sort out the active peptide fraction
from the inactive fraction in order to get a better picture of
which modifications yield antimicrobially active peptides.
The putative cluster of pneumococcins consists of 11
ORFs. In the cluster, two genes might be required for
proper modification of PneA1 and PneA2. These genes en-
code a single putative LanM-type modification enzyme and
a putative LanD-type flavoprotein. Flavoproteins catalyze
the oxidative decarboxylation of a C-terminal cysteine resi-
due involved in ring formation. A FAD-dependent flavopro-
tein catalyzes this reaction for mersacidin, a lantibiotic pro-
duced by Bacillus sp. (29). Another flavoprotein, which is
flavin mononucleotide (FMN) dependent, catalyzes the
same reaction for epidermin, a lantibiotic of S. epidermidis,
and this enzyme is essential for formation of a biologically
activity peptide (24). It is not known whether the putative
LanD-type flavoprotein of PneA1 and PneA2 performs a
similar function in this cluster. Because the original cluster
of pneumococcins contains LanM- and LanD-type modifi-
cation enzymes, peptides modified by NisB and NisC might
not be fully active by the lack of the oxidative decarboxyl-
ation. Furthermore, we do not know whether the native
dehydration and ring pattern is exactly similar to the one
installed heterologously by NisB and NisC. These factors
might explain the presumably suboptimal antimicrobial ac-
tivities and lack of synergism within this putative two-com-
ponent lantibiotic system. However, both peptides, PneA1
and PneA2, still showed significant antimicrobial activity.
The production of nonlantibiotic or lantibiotic chimeras with
a heterologous system has been reported using either closely
related or nonlantibiotic peptides. For example, production of
chimeric nonlantibiotic bacteriocin pediocin PA-1, which is
fused to the leader of lactococcin A and/or to enterocin P, or
enterocin A, which is fused to the leader of enterocin P, re-
sulted in the secretion of active peptides (13, 30, 31). These
TABLE 3. Susceptibility of M. flavus to NisBC-modified
PneA1 and PneA2 peptides
Sample




Nisin leader peptide PneA1 80 0.6
Nisin leader peptide PneA2 85 10 8.5
Nisin leader peptide PneA1 1




Empty sample NI NI
a NI, no inhibition. MICs are calculated using the molecular weights of the
mature peptides.


















































cases of successful production of biologically active bacterio-
cins concerns nonlantibiotic bacteriocins, which in contrast to
lantibiotics do not require posttranslational modifications for
antimicrobial activity. Production of class I lantibiotic chime-
ras, such as nisin/subtilin or subtilin/nisin, with either subtilin
or nisin expression machineries was performed successfully (1,
23). Of the amino acid residues of the leaders and mature
peptides of subtilin and nisin, 57% were identical (23). Studies
using lacticin 481 synthetase demonstrated its ability to pre-
pare other lantibiotics in the class II lacticin 481 family, includ-
ing nukacin ISK-1, mutacin II, and ruminococcin A (37).
In contrast, we show here for the first time that it is possible
to use the nisin synthetase system to produce, modify, and
secrete lantibiotics, from a very different source and class, that
exhibit considerable antimicrobial activity.
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